Key Points
- Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics on April 8 at an average price of $34.90 for $12,564, a trade executed under a pre-arranged Rule 10b5-1 plan that reduced his ownership by 0.13% to 286,516 shares (≈$9.999M).
- RAPP opened at $34.22, has a 52-week range of $7.73–$42.27 and a market cap of $1.64B; the company reported a quarterly EPS of ($0.72), missing estimates and reflecting a negative P/E.
- The stock carries a consensus rating of “Moderate Buy” with a $51.40 target amid mixed analyst views, and institutional investors like Capital International and Baker Bros. materially increased their stakes in recent quarters.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 360 shares of the stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $34.90, for a total transaction of $12,564.00. Following the completion of the sale, the insider owned 286,516 shares of the company's stock, valued at $9,999,408.40. This trade represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Rapport Therapeutics Stock Up 1.6%
Shares of NASDAQ RAPP opened at $34.22 on Friday. The firm has a 50-day simple moving average of $29.12 and a 200-day simple moving average of $28.15. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -11.96 and a beta of 1.09. Rapport Therapeutics, Inc. has a 52 week low of $7.73 and a 52 week high of $42.27.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.07). As a group, equities research analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.
Wall Street Analysts Forecast Growth
RAPP has been the subject of several recent analyst reports. TD Cowen restated a "buy" rating on shares of Rapport Therapeutics in a research report on Monday, March 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. Truist Financial upgraded shares of Rapport Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. Finally, Citigroup restated a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.40.
View Our Latest Research Report on Rapport Therapeutics
Institutional Investors Weigh In On Rapport Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Capital International Investors boosted its stake in Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company's stock worth $101,055,000 after buying an additional 800,000 shares during the period. Baker BROS. Advisors LP boosted its stake in Rapport Therapeutics by 181.2% during the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company's stock worth $45,949,000 after buying an additional 997,000 shares during the period. Maven Securities LTD purchased a new position in Rapport Therapeutics during the third quarter worth about $594,000. Arizona State Retirement System purchased a new position in Rapport Therapeutics during the fourth quarter worth about $234,000. Finally, Swedbank AB purchased a new position in Rapport Therapeutics during the fourth quarter worth about $3,434,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
